Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prodigiosene-4-hydroxytamoxifen conjugate 4c
- Development stage
- Preclinical
- Lead developer
- Dalhousie University
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
prodigiosene-4-hydroxytamoxifen conjugate 4c is a synthetic small molecule conjugate consisting of a tripyrrolic prodigiosene pharmacophore linked to a 4-hydroxytamoxifen (afimoxifene) targeting moiety via an ester linker. Developed by researchers at Dalhousie University, this conjugate is designed to selectively target estrogen receptor (ER)-positive breast cancer cells, such as the MCF-7 cell line. The 4-hydroxytamoxifen component binds to the estrogen receptor, facilitating cellular uptake, while the prodigiosene component acts as a transmembrane anion transporter, disrupting intracellular pH, inducing apoptosis, and exhibiting nanomolar-range antiproliferative activity.
- Other names
- prodigiosene-4-hydroxytamoxifen conjugate 4cprodigiosene4-hydroxytamoxifen conjugate 4cprodigiosene 4-hydroxytamoxifen conjugate 4cprodigiosene-tamoxifen conjugate 4c
02
Targets
ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on prodigiosene-4-hydroxytamoxifen conjugate 4c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prodigiosene-4-hydroxytamoxifen conjugate 4c.